1. Home
  2. UROY vs TECX Comparison

UROY vs TECX Comparison

Compare UROY & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Uranium Royalty Corp.

UROY

Uranium Royalty Corp.

HOLD

Current Price

$3.61

Market Cap

601.8M

Sector

N/A

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$27.50

Market Cap

554.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
UROY
TECX
Founded
2017
2019
Country
Canada
United States
Employees
N/A
60
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
601.8M
554.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UROY
TECX
Price
$3.61
$27.50
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$75.20
AVG Volume (30 Days)
2.2M
225.9K
Earning Date
03-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$279.20
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1,584.46
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.84
$14.39
52 Week High
$5.52
$35.99

Technical Indicators

Market Signals
Indicator
UROY
TECX
Relative Strength Index (RSI) 42.81 46.21
Support Level $3.54 $27.39
Resistance Level $4.07 $31.42
Average True Range (ATR) 0.24 1.80
MACD -0.03 -0.00
Stochastic Oscillator 5.52 34.59

Price Performance

Historical Comparison
UROY
TECX

About UROY Uranium Royalty Corp.

Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: